

July 28, 2022

Sodium Acetate Injection, USP
Supply Update

Dear Valued Customer,

Fresenius Kabi Canada is pleased to advise that supply of our **Sodium Acetate Injection, USP 4 mEq/mL Maxivial® 100 mL** will be available to our customers for an additional month. Allocations will be in place until **August 31, 2022**. Contract customers are allocated **100% of 100 mL demand plus 100% of 50 mL demand on a mL per mL basis (2 vials of 50 mL = 1 vial of 100 mL)**.

Please refer to our Healthcare Professional Communication “**Important Safety Information Sodium Acetate Injection, USP - Potential for the Presence of Particulate Matter**” dated May 6, 2022 for **important guidance relating to use of this product** (<https://www.fresenius-kabi.com/en-ca/documents/HC-approved-HPRC-Sodium-Acetate-Injection-UPDATE-EN-050622.pdf>).

Long term supply status is currently unknown; however, we assure you we are working diligently with our plants for resolution and updates can be expected in the weeks ahead. We strongly encourage all customers to use prudent conservation measures to extend the supply as long as possible.

DIN	Fresenius Kabi Product Code	MDP/ McKesson Product Code	Product Description	Supply Status August	Supply Status September
02139529	C3250	922833/ 594226	Sodium Acetate Injection, USP 4 mEq/mL SD Vial 50 mL	Backorder	Backorder Estimated Availability Date: TBD
02139529	C32B1	922821/ 955229	Sodium Acetate Injection, USP 4 mEq/mL Maxivial® 100 mL	Allocations to cover 100% of 100mL demand plus 100% of 50mL demand on a mL:mL basis (2 vials of 50 mL = 1 vial of 100 mL)	Backorder Estimated Availability Date: TBD

We recognize the difficulties and inconvenience that you may encounter as a result of our supply situation, and we thank you for your patience and understanding in this matter.

If you have any questions or concerns, please do not hesitate to contact customer service at (877) 821-7724.

Sincerely,



George Shamsoun
 Associate Director, Marketing – IV Drugs
george.shamsoun@fresenius-kabi.com